SCHEMBL405794

SCHEMBL405794

CN(CC(=O)OC(C)(C)C)Cc1cc(C#N)ccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ABCB1 P08183 8/20 0.42
POLB P06746 1/20 0.40
KCNH2 Q12809 3/20 0.36
SLC6A4 P31645 2/20 0.36
HTR2A P28223 2/20 0.36
PDK1 Q15118 1/20 0.36
PDK2 Q15119 1/20 0.36
PDK3 Q15120 1/20 0.36
PDK4 Q16654 1/20 0.36
NCEH1 Q6PIU2 1/20 0.36
FNTA P49354 3/20 0.35
FNTB P49356 3/20 0.35
SLC6A3 Q01959 1/20 0.34
HCRTR2 O43614 1/20 0.34
CTSL P07711 1/20 0.34
CTSB P07858 1/20 0.34
CTSS P25774 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL403900 0.92 HTT (0.54) HTTNPSR1ABCB1POLBPDK1
SCHEMBL2775844 0.88 ABCB1 (0.42) HTTNPSR1ABCB1POLBFNTA
SCHEMBL408930 0.88 ABCB1 (0.42) HTTNPSR1ABCB1POLBFNTA
SCHEMBL408771 0.84 ABCB1 (0.41) HTTNPSR1ABCB1POLBNCEH1
SCHEMBL406404 0.84 ABCB1 (0.41) HTTNPSR1ABCB1
SCHEMBL410797 0.83 ABCB1 (0.41) HTTNPSR1ABCB1POLB
SCHEMBL405751 0.82 ABCB1 (0.40) HTTNPSR1ABCB1SLC6A4FNTA
SCHEMBL410467 0.82 ABCB1 (0.40) HTTNPSR1ABCB1POLBFNTA
SCHEMBL408817 0.81 POLB (0.52) HTTABCB1POLBCTSLCTSB
SCHEMBL411371 0.78 POLB (0.42) HTTNPSR1ABCB1POLBFNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414341-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-09-13 EP disclosed
EP-2414342-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-05-31 EP disclosed
US-8815919-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2014-08-26 US disclosed
US-8802704-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-20120035226-A1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2012-02-09 US disclosed
EP-2414341-A2 OXADIAZOLE DERIVATIVES Merck Serono SA (CH) 2012-02-08 EP disclosed
EP-2414342-A1 OXADIAZOLE DERIVATIVES Merck Serono S.A. (CH) 2012-02-08 EP disclosed
US-20120022109-A1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2012-01-26 US disclosed
WO-2010115751-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2010-10-14 WO disclosed
WO-2010112461-A1 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2010-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022109-A1 OXADIAZOLE DERIVATIVES OXA1L, HLA-DRB1, SSB HTT 4073/4885NPSR1 3160/4885ABCB1 1198/4885
US-20120035226-A1 OXADIAZOLE DERIVATIVES OXA1L, HLA-DRB1, SSB HTT 4073/4885NPSR1 3160/4885ABCB1 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.